...Sunovion Pharmaceuticals Inc. and partner PsychoGenics Inc. (Paramus, N.J.) said SEP-363856 met the primary endpoint in the...
...is in January 2020. Sunovion is a subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506). PsychoGenics Inc....
...NA SEP-363856 is an antipsychotic targeting serotonin (5-HT1A) receptor and trace amine-associated receptor 1 (TAAR1). Brian Moy SEP-363856 PsychoGenics Inc. Sumitomo...

...have the right to pursue an IND submission for compounds evaluated with PsychoGenics’ SmartCube platform. PsychoGenics...
...SmartCube platform. PsychoGenics said Sunovion chose to move forward with the development of SEP-363856, while PsychoGenics...
...development of the compound and is eligible for royalties (see BioCentury, Oct. 12, 2015 ). PsychoGenics Inc....

...product was discovered under a 2007 deal with PsychoGenics (see BioCentury, Oct. 12, 2015 ). PsychoGenics Inc....
...Neuropsychiatric Inventory (NPI), Mini-Mental State Exam (MMSE) and safety Status: Phase II started Milestone: NA Chris Lieu SEP-363856 PsychoGenics Inc. Sumitomo...

...and head and neck cancers. Doogan, a partner at Mediqventures, and Emer Leahy, CEO of PsychoGenics Inc....

...The university granted PsychoGenics a license to a mouse model expressing human amyloid precursor protein (APP...
...plaque deposition in the cerebral cortex and hippocampus as early as three to four months. PsychoGenics...
...early Alzheimer’s disease-associated phenotypes. The university declined to provide further details or financial terms, and PsychoGenics...

...from PsychoGenics (see BioCentury, Jan. 20, 2014). Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif. PsychoGenics Inc....

...Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary and PsychoGenics extended for four years an August 2007 deal...
...one compound into clinical testing under the deal. The companies did not respond to inquiries. PsychoGenics Inc....

...enrollment next year. Amarantus has exclusive, worldwide rights, excluding countries in Asia, to eltoprazine from PsychoGenics...
...Phase II testing for intractable severe burns. Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif. PsychoGenics Inc....

...The university’s school of medicine granted PsychoGenics worldwide rights to an alpha synuclein (SNCA) transgenic mouse...
...partners did not respond to inquiries. University of California San Diego , La Jolla, Calif. PsychoGenics Inc....